Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathurin Fumery

Showing results (211-220 of 254) with videos related to

Pageof 26
Sort By:
Scandinavian Journal of Gastroenterology|July 12, 2022
Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort studyAntoine Meyer, Mathurin Fumery, Laurent Peyrin-Biroulet, et al.
Clinics and Research in Hepatology and Gastroenterology|November 20, 2020
Endoscopic balloon dilation of colorectal strictures complicating Crohn's disease: a multicenter studyMarion Tilmant, Mélanie Serrero, Florian Poullenot, et al.
Gut|January 26, 2017
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) studyYoram Bouhnik, Franck Carbonnel, David Laharie, et al.
Alimentary Pharmacology & Therapeutics|June 6, 2019
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort studyAurelien Amiot, Melanie Serrero, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases|July 11, 2022
Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 StudyAnthony Buisson, Mélanie Serrero, Laurie Orsat, et al.
Journal of Crohn'S & Colitis|May 7, 2019
Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort StudyBenedicte Caron, Laurent Peyrin-Biroulet, Benjamin Pariente, et al.
Inflammatory Bowel Diseases|June 2, 2017
Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel DiseaseAnthony Buisson, Florent Gonzalez, Florian Poullenot, et al.
The American Journal of Gastroenterology|November 6, 2020
Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAIDConstance Chapuis-Biron, Julien Kirchgesner, Benjamin Pariente, et al.
Alimentary Pharmacology & Therapeutics|December 19, 2022
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort studyMathurin Fumery, Antoine Defrance, Xavier Roblin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 19, 2022
Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO studyLucas Guillo, Benoit Flachaire, Jérôme Avouac, et al.
Pageof 26

Showing results (211-220 of 254) with videos related to

Sort By:
Pageof 26
Scandinavian Journal of Gastroenterology|July 12, 2022
Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort studyAntoine Meyer, Mathurin Fumery, Laurent Peyrin-Biroulet, et al.
Clinics and Research in Hepatology and Gastroenterology|November 20, 2020
Endoscopic balloon dilation of colorectal strictures complicating Crohn's disease: a multicenter studyMarion Tilmant, Mélanie Serrero, Florian Poullenot, et al.
Gut|January 26, 2017
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) studyYoram Bouhnik, Franck Carbonnel, David Laharie, et al.
Alimentary Pharmacology & Therapeutics|June 6, 2019
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort studyAurelien Amiot, Melanie Serrero, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases|July 11, 2022
Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 StudyAnthony Buisson, Mélanie Serrero, Laurie Orsat, et al.
Journal of Crohn'S & Colitis|May 7, 2019
Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort StudyBenedicte Caron, Laurent Peyrin-Biroulet, Benjamin Pariente, et al.
Inflammatory Bowel Diseases|June 2, 2017
Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel DiseaseAnthony Buisson, Florent Gonzalez, Florian Poullenot, et al.
The American Journal of Gastroenterology|November 6, 2020
Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAIDConstance Chapuis-Biron, Julien Kirchgesner, Benjamin Pariente, et al.
Alimentary Pharmacology & Therapeutics|December 19, 2022
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort studyMathurin Fumery, Antoine Defrance, Xavier Roblin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 19, 2022
Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO studyLucas Guillo, Benoit Flachaire, Jérôme Avouac, et al.
Pageof 26